



ImmunOs Therapeutics AG Appoints Leading U.S. Based Academic and Industry Oncology, Immunology, and Product Development Experts to the Scientific Advisory Board

Schlieren (Zurich Area), Switzerland. – August 7, 2017 – ImmunOs Therapeutics AG, a Swiss biotechnology company leading the next generation of innate and adaptive immunity focused immunotherapies for cancer, today announced the appointment of two leading U.S. scientists to its scientific advisory board.

- 1) Dr. Michael Curran from the University of Texas MD Anderson Cancer Center** and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, which coordinates development and production of clinical immunotherapeutic antibodies based on novel targets and preclinical reagents originating at MD Anderson. He also has established an independent lab at MD Anderson, where his group studies the origins of the immunosuppressive tumor microenvironment and how it can be disrupted to facilitate immune-mediated tumor rejection. At Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential papers describing how T-cell co-stimulatory pathways could be modulated in tandem to mediate immunologic rejection of melanomas in mice. He detailed how combination blockade of the T-cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of a majority of murine melanomas an unprecedented result that prompted the Food and Drug Administration to make this the first approved immunotherapy antibody combination. In addition, his subsequent immunologic studies of 4-1BB agonist antibodies earned him the Society for the Immunotherapy of Cancer’s prestigious Presidential Award

- 2) Dr. Darryl H. Patrick, DVM, PHD a Pharmaceutical Research and Development Executive** specializing in Nonclinical Development for over 30 years. Began at Merck/MSD Research Laboratories serving in numerous roles over 20 years ultimately serving as Vice President/Head, Worldwide Safety Assessment responsible for all nonclinical aspects for potential drug development candidates, including toxicologic evaluation, defining preclinical drug development candidate plans, interacting with drug development teams, preparation of regulatory submissions including INDs/NDAs,. Subsequently, was Vice President, Exploratory Development at Vertex Pharmaceuticals responsible for all nonclinical development activities and Clinical Pharmacology directing programs through to proof of concept. While at Vertex, was member of management team responsible for first NCE developed within the Company.

“We are excited to have such accomplished scientists and industry professionals join our team,” said Dr. Osiris Marroquin-Belaunzaran, Chief Scientific Officer at ImmunOs Therapeutics AG. “Their expertise and guidance will be instrumental as we advance our existing preclinical programs and expand our platform of novel immunomodulators focused on innate and adaptive immunity into clinic.”

“In addition to the current founding scientific team of Immuno-oncology and Immunology experts, our new SAB members add significant depth in several areas that are key to the company’s mission including cancer biology, immunology, preclinical and clinical strategy as we initiate plans for the next stage of development. Our new SAB members are well-recognized and represent some of the top academic institutions and leading pharmaceutical companies worldwide. We are honored and fortunate to be working with such a talented group of current and new advisors” said Sean R. Smith, Chief Executive Officer at ImmunOs Therapeutics AG.

About ImmunOs Therapeutics AG:

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing the next generation of novel human immunomodulatory proteins focused in innate and adaptive immunity. Our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.

ImmunOs Therapeutics AG lead program is a next generation, novel platform of targets that differ from the common competitor antibodies as they target diverse immunoregulatory receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (Macrophages and NK Cells) and Indirectly on the Adaptive Immune System by targeting MDSCs and thus allowing the expansion of T cells leading to a strong anti-tumor response in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications. For more information, please visit www.immunotherapeutics.com.



Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area)

info@immunotherapeutics.com